CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells
Matthias Braun(QIMR Berghofer Medical Research Institute), Tobias Bald(QIMR Berghofer Medical Research Institute), James S. Wilmott(The University of Sydney), Sophie Krumeich(QIMR Berghofer Medical Research Institute), Oltin T. Pop(University of St.Gallen), Kimberley Stannard(QIMR Berghofer Medical Research Institute), Michael Hölzel(University of Bonn), Lizeth G. Meza Guzman(The University of Melbourne), Brodie Quine(QIMR Berghofer Medical Research Institute), Amelia Roman Aguilera(QIMR Berghofer Medical Research Institute), Glen Kristiansen(University Hospital Bonn), Ailin Lepletier(Griffith University), Kunlun Li(Peking University), Dillon Corvino(University of Bonn), André Veillette(Montreal Clinical Research Institute), Ludovic Martinet(Centre National de la Recherche Scientifique), Jason Madore(QIMR Berghofer Medical Research Institute), Frank Vari(The University of Queensland), Dimo Dietrich(University of Bonn), Sandra E. Nicholson(The University of Melbourne), Andreas Möller(Chinese University of Hong Kong), Maria Villancanas Jorge(QIMR Berghofer Medical Research Institute), Elizabeth Ahern(Monash Health), William C. Dougall(Queensland University of Technology), Ashmitha Sundarrajan(QIMR Berghofer Medical Research Institute), Maike Effern(University of Bonn), Brett Hughes(Royal Brisbane and Women's Hospital), Eun Young Seo(Dong-A University), Luize G. Lima(QIMR Berghofer Medical Research Institute), Touraj Taheri(The University of Queensland), Kyohei Nakamura(QIMR Berghofer Medical Research Institute), Mark J. Smyth(Peter MacCallum Cancer Centre), Sally‐Ann Pearson(QIMR Berghofer Medical Research Institute), Sunyoung Ham(Chinese University of Hong Kong), Matthias Geyer(University of Bonn), Georgina V. Long(The University of Sydney), Martin Batstone(Queensland Health), Lambros T. Koufariotis(QIMR Berghofer Medical Research Institute), Sébastien Jacquelin(The University of Queensland), Richard A. Scolyer(The University of Sydney), Robert J. Johnston(Johns Hopkins University), Jennifer Landsberg(University Hospital Bonn), Mika Casey(QIMR Berghofer Medical Research Institute), Lukas Flatz(Leman University), Nazhifah Salim(QIMR Berghofer Medical Research Institute), Rui Li(Montreal Clinical Research Institute), Ashwini Raghavendra(QIMR Berghofer Medical Research Institute), Indrajit Das(QIMR Berghofer Medical Research Institute), Gabrielle Kelly(Griffith University)
Cited by 181
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k